Results 281 to 290 of about 5,278,927 (357)

Editorial: Accelerating cancer genomics research in Sub-Saharan Africa

Frontiers in Oncology
Folakemi T. Odedina, Folakemi T. Odedina, Solomon O. Rotimi, Solomon O. Rotimi, Abdou Azaque Zoure   +4 more
doaj   +1 more source

G protein-coupled receptors in prostate cancer: research progress and therapeutic targets. [PDF]

Front Cell Dev Biol
Xiong W, Zhou B, Shi J, Ni D, Xiong Z.
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Methods and Guidelines for Metabolism Studies: Applications to Cancer Research. [PDF]

Int J Mol Sci
Li M, Amend SR, Pienta KJ.
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Prostate Cancer-Research Advances in Early Detection. [PDF]

J Clin Med
Czerw A, Deptała A, Głowacka M, Partyka O, Pajewska M, Czerw N, Badowska-Kozakiewicz A, Sygit K, Kopczyński Z, Czarnywojtek P, Gąska I, Kaczmarski M, Banaś T, Grochans E, Grochans S, Cybulska AM, Schneider-Matyka D, Bandurska E, Ciećko W, Dykowska G, Sienkiewicz Z, Drobnik J, Pobrotyn P, Grata-Borkowska U, Furtak-Pobrotyn J, Sierocka A, Marczak M, Pokorna-Kalwak D, Kozlowski R.   +28 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Barriers to clinical cancer research participation: moving from inclusion to engagement when considering European migrants' recruitment. [PDF]

Trials
Millet N, Brzeska M, Czyznikowska B, Postavaru GI, Silina I, Darko N, Moss EL.   +6 more
europepmc   +1 more source